Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TNDM
stocks logo

TNDM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
276.85M
-2.05%
-0.082
-81.21%
248.88M
+6.17%
-0.412
-37.99%
266.93M
+10.91%
-0.291
-39.89%
Estimates Revision
The market is revising Downward the revenue expectations for Tandem Diabetes Care, Inc. (TNDM) for FY2025, with the revenue forecasts being adjusted by -0.17% over the past three months. During the same period, the stock price has changed by 64.63%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.17%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-3.77%
In Past 3 Month
Stock Price
Go Up
up Image
+64.63%
In Past 3 Month
Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 22.71 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 22.71 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
10 Hold
0 Sell
Moderate Buy
Current: 20.710
sliders
Low
14.00
Averages
22.71
High
55.00
Current: 20.710
sliders
Low
14.00
Averages
22.71
High
55.00
Morgan Stanley
Equal Weight
maintain
$17 -> $23
2025-12-02
New
Reason
Morgan Stanley
Price Target
$17 -> $23
2025-12-02
New
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Tandem Diabetes to $23 from $17 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Morgan Stanley
Equal Weight
maintain
$13 -> $17
2025-11-10
Reason
Morgan Stanley
Price Target
$13 -> $17
2025-11-10
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Tandem Diabetes to $17 from $13 and keeps an Equal Weight rating on the shares.
Baird
Neutral
maintain
$16 -> $18
2025-11-07
Reason
Baird
Price Target
$16 -> $18
2025-11-07
maintain
Neutral
Reason
Baird raised the firm's price target on Tandem Diabetes to $18 from $16 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results where pricing tailwinds help but pump volume pressures remain.
Barclays
NULL -> Overweight
maintain
$51 -> $55
2025-11-07
Reason
Barclays
Price Target
$51 -> $55
2025-11-07
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Tandem Diabetes to $55 from $51 and keeps an Overweight rating on the shares. The firm views the company's Q3 report as solid and sees a "healthy" pipeline.
Mizuho
Neutral
maintain
$16 -> $18
2025-11-07
Reason
Mizuho
Price Target
$16 -> $18
2025-11-07
maintain
Neutral
Reason
Mizuho raised the firm's price target on Tandem Diabetes to $18 from $16 and keeps a Neutral rating on the shares.
Goldman Sachs
David Roman
Neutral
maintain
$14 -> $16
2025-11-07
Reason
Goldman Sachs
David Roman
Price Target
$14 -> $16
2025-11-07
maintain
Neutral
Reason
Goldman Sachs analyst David Roman raised the firm's price target on Tandem Diabetes to $16 from $14 and keeps a Neutral rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Tandem Diabetes Care Inc (TNDM.O) is -20.66, compared to its 5-year average forward P/E of 41.53. For a more detailed relative valuation and DCF analysis to assess Tandem Diabetes Care Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
41.53
Current PE
-20.66
Overvalued PE
218.29
Undervalued PE
-135.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
146.10
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
377.06
Undervalued EV/EBITDA
-84.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.39
Current PS
0.00
Overvalued PS
7.67
Undervalued PS
1.11
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 870.81% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TNDM News & Events

Events Timeline

(ET)
2025-11-10
09:07:27
Tandem Diabetes Secures FDA Approval for Compatibility with Android Smartphones
select
2025-11-06 (ET)
2025-11-06
16:52:26
Tandem Diabetes confirms FY25 revenue projection of $1.0B, matching consensus estimate of $1.0B.
select
2025-11-06
16:51:44
Tandem Diabetes announces Q3 earnings per share of 31 cents, below consensus estimate of 34 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-04PRnewswire
Tandem Diabetes Faces Class Action Over Misleading Information Claims
  • Legal Investigation Initiated: Rosen Law Firm is investigating Tandem Diabetes Care for potentially issuing misleading business information, which may lead to securities claims from shareholders.
  • Stock Price Plunge: On August 7, 2025, Tandem Diabetes' stock fell 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, indicating serious market concerns over the company's information transparency.
  • Class Action Preparation: Rosen Law Firm is preparing a class action to seek compensation for affected investors, with no out-of-pocket fees required, providing legal support for harmed shareholders.
  • Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling similar cases.
[object Object]
Preview
7.0
12-01Globenewswire
Tandem Diabetes Faces Class Action Over Misleading Information
  • Legal Investigation Initiated: Rosen Law Firm is investigating Tandem Diabetes Care for potentially issuing misleading business information, which may lead to securities claims from shareholders.
  • Stock Price Plunge: On August 7, 2025, Tandem Diabetes' stock fell 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, indicating serious market concerns about the company's transparency.
  • Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, with no upfront costs for investors, which may encourage more affected shareholders to participate.
  • Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and influence in such cases.
[object Object]
Preview
7.0
11-29PRnewswire
Rosen Law Firm Investigates Potential Securities Claims for TNDM Shareholders
  • Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ:TNDM) for possibly issuing misleading business information, highlighting serious concerns regarding the company's transparency.
  • Stock Price Impact: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release about a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting a significant decline in market confidence regarding product safety.
  • Class Action Preparation: The firm is preparing a class action to recover losses for investors, demonstrating a strong commitment to protecting shareholder rights and potentially attracting more affected shareholders to participate.
  • Legal Service Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling complex securities cases.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tandem Diabetes Care Inc (TNDM) stock price today?

The current price of TNDM is 20.71 USD — it has increased 3.91 % in the last trading day.

arrow icon

What is Tandem Diabetes Care Inc (TNDM)'s business?

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.

arrow icon

What is the price predicton of TNDM Stock?

Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 22.71 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tandem Diabetes Care Inc (TNDM)'s revenue for the last quarter?

Tandem Diabetes Care Inc revenue for the last quarter amounts to 249.25M USD, increased 2.17 % YoY.

arrow icon

What is Tandem Diabetes Care Inc (TNDM)'s earnings per share (EPS) for the last quarter?

Tandem Diabetes Care Inc. EPS for the last quarter amounts to -0.31 USD, decreased -11.43 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tandem Diabetes Care Inc (TNDM)'s fundamentals?

The market is revising Downward the revenue expectations for Tandem Diabetes Care, Inc. (TNDM) for FY2025, with the revenue forecasts being adjusted by -0.17% over the past three months. During the same period, the stock price has changed by 64.63%.
arrow icon

How many employees does Tandem Diabetes Care Inc (TNDM). have?

Tandem Diabetes Care Inc (TNDM) has 2650 emplpoyees as of December 05 2025.

arrow icon

What is Tandem Diabetes Care Inc (TNDM) market cap?

Today TNDM has the market capitalization of 1.40B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free